Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study

Weintraub, Daniel; Sohr, Mandy; Potenza, Marc N.; Siderowf, Andrew; Stacy, Mark; Voon, Valerie; Whetteckey, Jacqueline; Wunderlich, Glen; Lang, Anthony E.

doi:10.1002/ana.22164

Cited by 139 publications

(94 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A post-hoc analysis of a large multi-centred epidemiological study showed a significant association between amantadine use and ICBs (17.6% of patients on amantadine vs. 12.4% of those not on amantadine) (Weintraub et al, 2010b). More studies are necessary to determine the exact effect amantadine has on ICBs because it is already used in PD and is known to have a beneficial effect on motor symptomatology.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson׳s disease

Tanwani

Fernie

Nikčević

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

Impulse Control Disorders (ICDs) are a set of behaviours characterised by impulsivity despite known harm. Related to ICDs is the dopamine dysregulation syndrome (DDS), which is characterised by an addiction-like consumption of dopaminergic medication and punding.These behaviours all have an increased prevalence in Parkinson's disease (PD). The aim of this review is to identify treatments available for patients suffering from ICDs, DDS and punding in PD. Searches of The Cochrane Controlled Trials Register, Embase, Medline and PsychInfo were conducted, using the entire timescale available. Seven out of the 688 papers retrieved met the inclusion criteria and were considered in this systematic review. One class I study, one class II study, and five class IV studies were identified. All studies demonstrated a positive effect on ICDs in PD. Research in this field is still in its early stages. At present, there is insufficient evidence to recommend any treatment over another. There is a need for more methodologically robust research, using larger, more generalizable samples, randomisation and meaningful follow-up periods. Additionally, the use of a validated outcome measures should be implemented in future research efforts.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson׳s disease

Tanwani

Fernie

Nikčević

et al. 2015

Psychiatry Research

View full text Add to dashboard Cite

show abstract

“…Moreover, in a large cross-sectional study of ICB, amantadine use was associated with a higher incidence of at least one active ICB when compared to no amantadine use. 33 In addition to ICB-specific measures, the CBTbased intervention also seemed to benefit depression and anxiety, which are commonly reported comorbidites, 6 as well as measures relating to work and social function. These findings are in keeping with a conceptual model which makes dysphoria a central component of PD-ICB.…”

Section: Executive Dysfunctionmentioning

confidence: 99%

Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers

Okai

Askey-Jones²,

Samuel³

et al. 2013

Neurology

170

127

View full text Add to dashboard Cite

Objective: To test the effects of a novel cognitive-behavioral therapy (CBT)-based intervention delivered by a nurse therapist to patients with Parkinson disease (PD) with clinically significant impulse control behaviors (ICB).Methods: This was a randomized controlled trial comparing up to 12 sessions of a CBT-based intervention compared to a waiting list control condition with standard medical care (SMC). A total of 27 patients were randomized to the intervention and 17 to the waiting list. Patients with a Mini-Mental State Examination score of ,24 were excluded. The coprimary outcomes were overall symptom severity and neuropsychiatric disturbances in the patients and carer burden and distress after 6 months. Secondary outcome measures included depression and anxiety, marital satisfaction, and work and social adjustment in patients plus general psychiatric morbidity and marital satisfaction in carers.Results: There was a significant improvement in global symptom severity in the CBT intervention group vs controls, from a mean score consistent with moderate to one of mild illness-related symptoms (x 2 5 16.46, p , 0.001). Neuropsychiatric disturbances also improved significantly (p 5 0.03), as did levels of anxiety and depression and adjustment. Measures of carer burden and distress showed changes in the desired direction in the intervention group but did not change significantly. General psychiatric morbidity did improve significantly in the carers of patients given CBT.Conclusions: This CBT-based intervention is the first to show efficacy in ICB related to PD in terms of patient outcomes. The hoped-for alleviation of carer burden was not observed. The study demonstrates the feasibility and potential benefit of a psychosocial treatment approach for these disturbances at least in the short term, and encourages further larger-scale clinical trials.

show abstract

“…4,7 However, an important unanswered question is whether PD itself confers an altered risk for ICDs. Preliminary comparison studies suggest that ICDs are more common in treated PD patients than in healthy controls (HCs).…”

mentioning

confidence: 99%

Screening for impulse control symptoms in patients with de novo Parkinson disease

Weintraub

Papay

Siderowf³

2013

Neurology

179

122

View full text Add to dashboard Cite

Objective: To determine the frequency and correlates of impulse control and related behavior symptoms in patients with de novo, untreated Parkinson disease (PD) and healthy controls (HCs).Methods: The Parkinson's Progression Markers Initiative is an international, multisite, case-control clinical study conducted at 21 academic movement disorders centers. Participants were recently diagnosed, untreated PD patients (n 5 168) and HCs (n 5 143). The outcome measures were presence of current impulse control and related behavior symptoms based on recommended cutoff points for the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (QUIP)-Short Form.Results: There were 311 participants with complete QUIP data. Frequencies of impulse control and related behavior symptoms for patients with PD vs HCs were as follows: gambling (1.2% vs 0.7%), buying (3.0% vs 2.1%), sexual behavior (4.2% vs 3.5%), eating (7.1% vs 10.5%), punding (4.8% vs 2.1%), hobbyism (5.4% vs 11.9%), walkabout (0.6% vs 0.7%), and any impulse control or related behavior (18.5% vs 20.3%). In multivariable models, a diagnosis of PD was not associated with symptoms of any impulse control or related behavior (p $ 0.10 in all cases).Conclusions: PD itself does not seem to confer an increased risk for development of impulse control or related behavior symptoms, which further reinforces the reported association between PD medications and impulse control disorders in PD. Given that approximately 20% of patients with newly diagnosed PD report some impulse control or related behavior symptoms, long-term followup is needed to determine whether such patients are at increased risk for impulse control disorder development once PD medications are initiated. Impulse control disorders (ICDs), including compulsive gambling, buying, sexual behavior, and eating, are common and clinically significant in Parkinson disease (PD).1 Other compulsive behaviors reported to occur include punding (excessive repetition of non-goal directed activity), 2 hobbyism (excessive repetition of more complex activities), 3 and walkabout (aimless wandering).2 In a recent large observational study of patients with treated PD, an ICD was identified in 14% of patients. 4 Prevalence rates for punding range from 1% to 14%, 5,6 whereas the prevalence of hobbyism and walkabout are not known.The association between PD medications and ICDs in PD is well established. 4,7 However, an important unanswered question is whether PD itself confers an altered risk for ICDs. Preliminary comparison studies suggest that ICDs are more common in treated PD patients than in healthy controls (HCs). 8,9 In the only published study assessing newly diagnosed, untreated PD patients, 18% screened positive for impulse control symptoms, a number similar to HCs.

show abstract

Amantadine use associated with impulse control disorders in Parkinson disease in cross‐sectional study

Cited by 139 publications

References 18 publications

A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson׳s disease

A systematic review of treatments for Impulse Control Disorders and related behaviours in Parkinson׳s disease

Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers

Screening for impulse control symptoms in patients with de novo Parkinson disease

Contact Info

Product

Resources

About